Board Certified in Radiation Oncology

Specializes in Treatment of Prostate Cancer including Brachytherapy/Seed therapy

John Sylvester, MD

 

BRIAN SCHOFIELD, MDDr. Sylvester is a board-certified Radiation Oncologist with a sub-specialty in the treatment of prostate cancer including brachytherapy / seed therapy.

 

 
 
  • Board Certified in Radiation Oncology
  • Education: Bachelor of Arts, Biological Sciences, UCSB, Santa Barbara, Calif.
  • Medical Degree: UCLA, Los Angeles, Calif.
  • Residency: UCLA Department of Radiation Oncology, Los Angeles, Calif.
  • Fellowship: American Cancer Society/Chief Resident, UCLA Department of Radiation Oncology, Los Angeles, Calif.
  • Certification: Board Certified, American Board of Radiology
  • Member: American Brachytherapy Society, American Society of Therapeutic Radiation Oncology, American College of Radiology
     
Over the past 2 decades, Dr. Sylvester has performed over 3700 prostate brachytherapy procedures. He has developed, and assisted in the development, of several technical improvements in the IMRT and Brachytherapy prostate cancer treatments including:
 
- How to better visualize the urethra during the procedure. 
- How to optimally utilize R.A.P.I.D. strand. 
- He was the first physician in the U.S. to use I125 Echo Seed, a more visible (on ultrasound) radioactive seed. 
- He was the lead Seattle investigator in a gene therapy protocol for salvage of external beam radiation therapy failures.
- He initiated the image-guided intensity modulated radiation therapy (IG-IMRT) approach used at the Swedish Cancer Institutes’ Radiation Oncology centers, for more precise Intensity Modulated Radiation Therapy (IMRT) for prostate cancer.
- He treated the first patient in the world with the first commercially available Calypso 4-D real-time image guidance unit for prostate cancer IMRT.
- He co-authored the white paper on Calypso 4-D IG-IMRT. 
- He worked with Oncura/General Electric to help create THINStrand, a new seed that is 42% thinner than standard sized seeds (less trauma) and is the first physician to use that new seed.
- He is the lead investigator in a multi-institutional protocol evaluating the quality of life outcomes of patients treated with IMRT plus a Cesium seed implant boost.
- Dr. Sylvester worked with the lead Brachytherapists at MDAH and Princess Margaret Hospital on a new brachytherapy outcomes nomogram to replace the outdated and inaccurate nomogram that is in current use.
- Reviews articles for acceptance to medical journals: International Journal Radiation Oncology Biology Physics, European Urology and Brachytherapy
- He is the first physician in the USA to use SpaceOAR in IG-IMRT prostate cancer patients as part of a randomized FDA protocol hoping to further reduce side effects of prostate cancer IG-IMRT.
- Named one of Sarasota’s Best Physicians in 2012 in Sarasota Magazine (as voted on by peers) 
- He was one of the four clinicians who wrote the ABS guidelines used by prostate cancer Brachytherapists worldwide.
 
The above work has led Dr. Sylvester to being called upon to present at national and international conferences on prostate cancer on a regular basis including: the World Congress of Endourology (Holland), American Society of Clinical Oncology, Urologic Society of Australasia (Melbourne), and European Association of Urology in Germany, GEC-ESTRO/WCB conferences in Europe, and multiple times at the Annual American Society of Therapeutic Radiation Oncology (ASTRO) Conference, the Annual ABS (American Brachytherapy Society) Conference, The Annual Scottsdale Prostate Cancer Symposium, and The Annual Seattle Prostate Institute Advanced Brachytherapy Conferences. He was chosen to debate prostate cancer treatment techniques at the 2011 ABS meeting and moderate at the GEC-ESTRO in Spain in 2012.
 

Contact Florida Medical Retreat 

**1 - John E. Sylvester M.D., Peter D. Grimm D.O., Jason Wong M.D., et al. “15 year Biochemical Relapse-Free Survival following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience,” Int J Radiat Oncol Biol PhysVol 2011;81(2); 376-381